

## **ASX ANNOUNCEMENT**

### **BLOCK TRADE TO INSTITUTIONAL INVESTORS – APPENDIX 3Y**

Wellington, NZ, 12 September 2019: [Volpara Health Technologies](#) Limited (“Volpara”; ASX: VHT), a medical technology company whose AI imaging algorithms assist the early detection of breast cancer, today advised that a group of founders and early investors, some of whom are Directors, have sold a portion of shares to institutional investors, as detailed in the ASX Appendix 3Y Notices also lodged today.

Last week, the Company’s CEO conducted a series of investor roadshows across Australia which culminated in an unsolicited approach from a broker on behalf of several international and domestic institutions that wanted to purchase shares but were unable to build a suitable position on market.

Dr Ralph Highnam, Volpara CEO, commented: “We’ve been on the radar of many of the big domestic and international institutions since the capital raise early this year, but not all of those parties were able to participate in the raise due to demand. Upon receiving the approach to cross the parcel of shares, the Board considered the offer and agreed that it would be beneficial for the Company and its shareholders to strengthen its institutional shareholder base and increase the proportion of stock held in free float.”

Mr Paul Reid, VHT Chair, commented: “These Directors, founders, and early investors have shown their commitment to the Company over the past 10 years. I’m pleased that this orderly transfer has been facilitated to allow more institutional shareholders to join the register, and allow the Directors, founders, and early investors to realise some of their long-held investment in Volpara. These individuals remain totally committed to the business and its work in the early detection and, ultimately, prevention of breast cancer. Furthermore, the Directors advise they have no intention to sell further shares in the foreseeable future.”

The block trade involved 6.1m shares, amounting to approximately 2.8% of the VHT-issued capital. The various parties sold approximately 12% of their respective holdings, reducing their combined holdings to approximately 23% of the VHT-issued capital.

ENDS.

#### **For further information, please contact:**

Ralph Highnam, CEO  
Volpara Health Technologies  
[ralph.highnam@volparasolutions.com](mailto:ralph.highnam@volparasolutions.com)  
t: +64 21 149 0541

Trevor Chappell  
WE Buchan  
[tchappell@we-buchan.com](mailto:tchappell@we-buchan.com)  
t: +61 3 9866 1215

#### **About Volpara Health Technologies Limited (ASX: VHT)**

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT’s clinical applications for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice management software helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 38 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$95 million, including A\$55 million in June 2019. VHT is based in Wellington, New Zealand.

For more information, visit [www.volparasolutions.com](http://www.volparasolutions.com).